Anti-inflammatory Effect of Protocatechuic Aldehyde on Myocardial Ischemia/Reperfusion Injury In Vivo and In Vitro

Guo Wei,¹ Yue Guan,¹ Ying Yin,¹ Jialin Duan,¹ Dan Zhou,¹ Yanrong Zhu,¹ Wei Quan,¹ Miaomiao $Xi^{1,2}$ and Aidong Wen^{1,2}

> Abstract—Myocardial ischemia/reperfusion (MI/R) injury, in which inflammatory response plays a vital role, is frequently encountered in clinical practice. The present study was aimed to investigate the anti-inflammatory effect and the possible mechanism of protocatechuic aldehyde (PAl) on MI/R injury both in vivo and in vitro. The rat model of MI/R injury was induced by ligation of the left anterior descending coronary artery for 30 min, followed by 3-h reperfusion, and pretreatment with PAl could protect the heart from MI/R injury by reducing myocardial infarct size and the activities of creatine kinase-MB and cardiac troponin I (cTn-I) in serum. Also, PAl administration markedly reduced cellular injury induced by simulated ischemia/reperfusion (SI/R) in cultured neonatal rat cardiomyocytes, which was evidenced by increased cell viability, reduced lactate dehydrogenase and cTn-I activities in the culture medium, and greatly decreased percentage of cell apoptosis. Moreover, the levels of tumor necrosis factor- α , interleukin-6, intracellular adhesion molecule-1, phosphorylated I κ B- α , and the nuclear translocation of nuclear factor-kappa B (NF- κ B) were all evidently decreased by PAI both in vivo and in vitro. Taken together, these observations suggested that PAl could exert great protective effects against MI/R injury in rats and SI/R injury in cultured neonatal rat cardiomyocytes, and the cardioprotective mechanism might be involved in the suppression of inflammatory response via inhibiting the NF-κB signaling pathway.

> KEY WORDS: protocatechuic aldehyde; anti-inflammatory; cardiomyocytes; myocardial ischemia/reperfusion; nuclear factor-kappa B.

INTRODUCTION

Myocardial ischemia/reperfusion (MI/R) injury is a common clinical entity, which occurs in many situations including angioplasty, coronary bypass surgery, cardiac transplantation, and thrombolytic therapy. Despite the multiple mechanisms proposed to underlie the pathology, including energy metabolic disturbance, oxidative damage, and calcium overload [\[1](#page-9-0)], inflammatory responses have gotten increased attention. It has been established that MI/R injury is closely associated with a strong inflammatory response [\[2](#page-9-0), [3](#page-10-0)]. A vast body of evidence suggested a critical role for inflammatory cascades mediated by cytokines and adhesion molecules including tumor necrosis factor (TNF) α, interleukin (IL)-6, and intracellular adhesion molecule (ICAM)-1 in MI/R process [[4](#page-10-0)–[6](#page-10-0)]. In addition, numerous experimental studies have shown excellent cardioprotection with the use of specific anti-inflammatory measures [[7](#page-10-0)–[9](#page-10-0)]. Therefore, therapeutic strategies aimed at preventing the inflammatory process may be a reasonable choice for the treatment of related heart diseases.

The root of Salvia miltiorrhiza (Lamiaceae), commonly known as Danshen, is one of the most popular traditional herbal medicines in China. Ample clinical and experimental evidences have implicated a critical role for Danshen in the pathogenesis of MI/R injury [[10](#page-10-0)–[12\]](#page-10-0). Protocatechuic aldehyde (PAl) {benzaldehyde,

Guo Wei, Yue Guan, Ying Yin, and Jialin Duan contributed equally to this work.

¹ Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China 2
² To whom correspondence should be addressed at Department of

Pharmacy, Xijing Hospital, The Fourth Military Medical University, Xi'an, 710032, China. E-mail: handsomfish@yahoo.com.cn; E-mail: adwen-2012@hotmail.com

^{0360-3997/13/0300-0592/0 @ 2012} Springer Science+Business Media New York

3, 4-dihydroxy} (Fig. 1) is one of the active watersoluble compounds derived from Danshen. Studies have demonstrated that PAl can exert a strong anti-inflammatory effect via suppressing the expression of ICAM-1, vascular cell adhesion molecule (VCAM)-1, and CD40 protein in human umbilical vein endothelial cells [\[13](#page-10-0), [14](#page-10-0)]. However, whether PAl plays a direct role against the inflammation mediated by cardiomyocytes in ischemia/ reperfusion (I/R) process has not been clarified so far, as well as whether activation of nuclear factor-kappa B (NF-κB) plays a pivotal role in inflammatory response during MI/R injury [[15\]](#page-10-0). Thus, in the present study, we sought to investigate (1) whether PAl may inhibit inflammation mediated by cardiomyocytes in MI/R injured rat model and simulated ischemia/reperfusion (SI/R) injured cell model, (2) whether the anti-inflammatory effect of PAl is involved in the NF-κB signaling pathway, and (3) whether suppression of the inflammatory response afforded by PAl may have a beneficial effect on MI/R injury.

MATERIALS AND METHODS

Materials and Animals

PAl (molecular weight 138.12, purity >99 %) was supplied by the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Dulbecco's Modified Eagle's Medium (DMEM) and other cell culture supplies were purchased from Gibco BRL (Grand Island, NY, USA). MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], TTC (2, 3, 5-triphenyltetrazolium chloride), and Evans blue were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Rabbit monoclonal antibodies to NF-κB (p65), ICAM-1, and rabbit polyclonal antibodies specific

for β-actin, PCNA, were the products of Cell Signaling (Beverly, MA, USA). All materials for sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS– PAGE) were obtained from Bio-Rad (Bio-Rad Laboratories, Hercules, CA, USA).

Sprague–Dawley rats including neonatal rats were obtained from the animal research center at the Fourth Military Medical University, Xi'an, China. The experiments were performed in adherence with the National Institutes of Health Guidelines for the Use of Laboratory Animals and were approved by the Fourth Military Medical University Committee on Animal Care.

Rat Model of Myocardial Ischemia/Reperfusion Injury

Rat model of MI/R injury was produced by ligation of the left anterior descending coronary artery (LAD), as described previously [[16\]](#page-10-0). Briefly, rats were anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneally). They were artificially ventilated using a volume-regulated respirator. The heart was exposed via a left thoracotomy and the left coronary artery was ligated 2– 3 mm from its origin between the pulmonary artery conus and the left atrium using a 6-0 silk suture. After 30 min of ischemia, reperfusion was established by releasing the slipknot for 3 h.

Experimental Protocol In Vivo

Sixty rats weighing 200–250 g were randomly divided into five experimental groups. There were 12 rats in each group: (1) Sham group, silk was drilled underneath the LAD but the LAD was not ligated; (2) Model group, the LAD was ligated for 30 min and then allowed 3-h reperfusion with receiving vehicle (saline, intravenously); and (3) three PAl-treated groups, different doses (5, 10, and 20 mg/kg body weight, respectively) of PAl were administered via tail vein injection twice daily for three consecutive days and the last dose was given 30 min before the coronary occlusion.

After 3-h reperfusion, blood samples were collected from abdominal aorta (six rats in each group) for enzyme-linked immunosorbent assay (ELISA) to detect the release of CK-MB, cTn-I, TNF-α, IL-6, and ICAM-1 (Jiancheng Bioengineering Institute, Nanjing, China) in serum according to the manufacturers' instructions. The animals were then sacrificed and the hearts were harvested for Western blot analysis. Myocardial infarct size was measured in the remaining Fig. 1. Chemical structure of PAl. six rats in each group.

Myocardial infarct size was measured by means of a double-staining technique adapted from a previous method [\[17](#page-10-0)] using 3 % Evans blue and 2 % TTC. Specifically, at the end of reperfusion, the ligature around the LAD was retied and 2 ml of 3 % Evans blue dye was injected into the jugular vein. The dye was circulated and uniformly distributed, except in the portion of the heart previously perfused by the occluded coronary artery. The heart was quickly excised, frozen at −20 °C, and the entire ventricular tissue was crosssectioned into five slices. The slices were then counterstained with 2 % TTC prepared with phosphate buffer (pH 7.8) for 15 min at 37 \degree C and photographed after overnight storage in 4 % paraformaldehyde. The areas stained with Evans blue (area not at risk), TTC (red staining, ischemic but viable myocardium, area at risk, AAR), and TTC-negative area (white area, infarct size, IS) were measured digitally using Image Pro Plus software (Media Cybernetics, USA). The myocardial infarct size was measured and expressed as a percentage of infarct size over total AAR.

Cell Culture and Simulated Ischemia/Reperfusion Injury Model

Neonatal rat cardiomyocytes from 1- to 2-day-old Sprague–Dawley rats were obtained and purified as the previous method [[18\]](#page-10-0). Cells were routinely cultured in high-glucose DMEM with 10 % fetal bovine serum (v/ v), 100 U/ml penicillin, and 100 mg/ml streptomycin, and maintained in an atmosphere of 95 % air and 5 % CO₂ at 37 °C. The cells were seeded at a density of $5 \times$ $10⁴$ cells/ml in 24-well plates for Hoechst 33258 staining and 5×10^5 cells/ml in six-well plates for biochemical indicators determination and Western blot analysis. The medium was replaced every 2 days, and cells were subjected to experimental procedures at 80–90 % confluence.

Simulated ischemia/reperfusion was performed as described previously [[19](#page-10-0)]. Briefly, cells were first transferred into "ischemic buffer", which was used to simulate the extracellular milieu of myocardial ischemia in vivo. Then plates of cultured cardiomyocytes were placed in a hypoxic incubator (37 °C, 95% N_2 , 5% CO2). After 2 h of incubation, the cells were subjected to reperfusion by replacing the "ischemic buffer" with routine culture medium, followed by incubation under normal conditions (37 °C, 95 % air, 5 % CO₂) for 4 h.

Experimental Protocol In Vitro

The neonatal rat cardiomyocytes were randomly divided into different groups. (1) In the control (Con) group, cardiomyocytes were cultured under normal conditions for 6 h. (2) The SI/R group was operated on as described previously. (3) In the PAl-treated groups $(SI/R + PAI)$, PAI (0.25, 0.5, and 1.0 mM) was added to the cell medium 24 h prior to the start of ischemia.

Cell Viability Assay

Cell viability was determined by a Microculture Tetrazolium (MTT) assay. Cells were seeded at a density of 1×10^4 cells/well in 96-well cell culture plates. Following exposure, 150 μl of the MTT solution (0.5 mg/ml) was added into each well, and then the plates were incubated for an additional 4 h at 37 °C. The medium was then removed and the metabolized MTT was solubilized with 150 μl DMSO. The absorbance of the solubilized blue formazan crystals was read at 490 nm. The percent viability was defined as the relative absorbance of treated versus that of untreated control cells.

Determination of LDH, cTn-I, TNF- α , and IL-6 Releases in Culture Medium

LDH [[20\]](#page-10-0) and cTn-I [\[21](#page-10-0)] are two reliable biomarkers of myocyte injury. In order to confirm the degree of cardiomyocytes injury in SI/R, we determined the activities of LDH and cTn-I in the culture medium using corresponding bi-antibodies sandwich ELISA kits according to the manufacturers' instructions (Jiancheng Bioengineering Institute). The activities of LDH and cTn-I in different groups were expressed as percentage of control.

TNF- α and IL-6 are two key proinflammatory cytokines released by cardiomyocytes in response to SI/R [\[22](#page-10-0)]. The levels of TNF- α and IL-6 in the culture medium were also determined by using an ELISA method (Jiancheng Bioengineering Institute) and expressed as picograms per milliliter.

Apoptosis Assay

Apoptosis is an important form of cell death in MI/ R injury [[23\]](#page-10-0). In the present study, apoptotic cells were confirmed by Hoechst 33258 staining. The staining process is as follows: after different treatments, cells were fixed with 4 % paraformaldehyde and then stained with Hoechst 33258 (1 μg/ml in PBS) for 10 min at room temperature. After three rinses with PBS, the nuclear morphology of the cells was detected under a fluorescence microscope with an appropriate filter. The cells showed distinctive condensed and/or fragmented nuclear structure were categorized as apoptotic cells.

To further quantify the level of apoptosis in different groups, double staining with Annexin V–FITC and propidium iodide (PI) was performed according to the manufacturer's instructions (Keygen Biotech, Nanjing, China). Cells were harvested and washed twice with PBS after the experimental procedures. Then cells (1×10^6) were resuspended in binding buffer, into which 5 μl Annexin V–FITC and PI were subsequently added. The mixture was incubated for 15 min in the dark at room temperature. Cellular fluorescence was then measured by bivariate flow cytometry using a FACS-SCAN (FACSCalibur; BD Biosciences, San Jose, CA, USA) and analyzed by CellQuest software. Quadrant dot plot was introduced to identify living and apoptotic cells and cells in early or late phase of apoptosis. Living cells were identified as double negative for Annexin V–FITC and PI. Early apoptotic cells were branded as Annexin V–FITC positive only and cells in late apoptosis were recognized as double positive for Annexin V–FITC and PI. The rate of apoptosis was determined as the percentage of Annexin V–FITC-positive cells.

Preparation of Protein Extractions and Western Blot Analysis

Cytosolic and nuclear proteins were extracted from heart tissue and cultured myocytes, using NE-PER nuclear and cytoplasmic extraction reagents according to the manufacturer's instructions (Thermo Scientific, USA). The protein concentration of each sample was measured using a Bio-Rad Protein assay kit (Bio-Rad, CA, USA). After quantitation of protein concentration, denatured protein was separated by SDS–PAGE and then transferred to polyvinylidene difluoride (PVDF) membranes. After being blocked with 5 $\%$ (w/v) non-fat milk at 37 °C for 30 min, membranes were incubated overnight at 4 °C with primary antibodies to NF-κB (p65), IκB-α, ICAM-1, β-actin, and PCNA, respectively. After three washings in TBS-T, the membranes were incubated for 30 min with a horseradish peroxidase conjugated secondary antibody diluted in TBS-T. The blots were visualized using the enhanced chemiluminescence method, and the bands were scanned and quantified by densitometric analysis.

Statistical Analysis

Data were expressed as mean \pm SD. Statistical analysis was performed by one-way analysis of variance (ANOVA) followed by an LSD test for multiple comparisons, using SPSS version 18.0 statistical software. A value of $P \leq 0.05$ was considered statistically significant.

RESULTS

PAl Protected the Rats from MI/R Injury

As reliable indicators of MI/R injury, infarct size, and the activities of CK-MB, cTn-I in serum were measured. And as illustrated in Fig. [2a and b](#page-4-0), 30-min ischemia followed by 3-h reperfusion resulted in development of substantial myocardial infarcts, which were significantly attenuated by PAl (10 and 20 mg/kg) treatment $(P<0.01$, compared with Model group). Besides, Fig. [2c and d](#page-4-0) showed that the elevated activities of CK-MB and cTn-I in serum resulted from MI/R were also decreased markedly by the administration of PAl (10 and 20 mg/kg) $(P<0.05, P<0.01)$.

PAl Reduced the Serum Levels of Inflammatory Mediators Following MI/R

Considering the key roles of TNF-α, IL-6, and ICAM-1 in the pathophysiology of inflammatory injury caused by MI/R, we measured the levels of these three inflammatory mediators in serum. As shown in Table [1](#page-4-0), the levels of TNF- α , IL-6, and ICAM-1 were all notably increased in the Model group compared with the Sham group $(P<0.01)$, but decreased significantly, though to different degrees, by PAl (10 and 20 mg/kg) $(P<0.05, P<0.01)$.

Appropriate Doses of PAl for In Vitro Experiments were Confirmed

To explore suitable doses of PAl employed in subsequent *in vitro* study, we first examined the depression effect of different concentrations of PAl (0– 3.0 mM) on the viability of neonatal rat cardiomyocytes cultured in normal conditions, using an MTT assay. As seen in Fig. [3a,](#page-5-0) PAl did not significantly affect cell viability at concentrations below 1.0 mM, and this dose was selected as the maximal concentration for the subsequent studies.

Fig. 2. The effects of PAl on myocardial damage in rats subjected to MI/R. a Representative photomicrographs of heart sections stained by Evans blue and TTC in different treatment groups. b The effect of PAl on myocardial infarct sizes (IS) expressed as percent of total ischemic–reperfused area (area-at-risk, AAR). c The effect of PAl on the activity of CK-MB in serum of rats subjected to MI/R. d The effect of PAl on the activity of cTn-I in serum of rats subjected to MI/R. The activities of LDH and cTn-I were detected by ELISA and expressed as percentage of Sham. Data are presented as mean \pm SD (n=6). $^{#}P$ < 0.01 vs. Sham group; ** P < 0.05, * P < 0.01 vs. Model group.

PAl Alleviated SI/R-Induced Cell Viability Loss

Cell viability was determined by MTT assay. The result is shown in Fig. [3b](#page-5-0). Exposed to SI/R, there were only $59.42 \pm$ 3.04 % viable cells ($P < 0.01$, compared with the Con group). However, PAl (0.5 and 1.0 mM), to a great degree, protected the neonatal rat cardiomyocytes against SI/R-induced cell viability loss, and restored cell survival to $75.45\pm3.56\%$ and 80.35 \pm 2.59 % (*P*<0.01, compared with SI/R group).

PAl Attenuated the Activities of LDH and cTn-I in the Culture Medium

As two markers of cardiomyocyte injury, the LDH and cTn-I activities in the culture medium were markedly elevated in the SI/R group compared with the Con group $(P<0.01)$, but were significantly decreased by PA1 (0.25, 0.5, and 1.0 mM) $(P<0.05, P<0.01)$ (Fig. [4\)](#page-5-0).

Treatment (mg/kg)	TNF- α (pg/ml)	IL-6 (pg/ml)	$ICAM-1$ (ng/ml)	
Sham	21.16 ± 9.31	100.45 ± 14.36	0.53 ± 0.12	
Model	68.28 ± 11.41 ***	$235.00 \pm 28.54***$	1.68 ± 0.26 ***	
MI/R +PAl (5)	63.95 ± 13.52	218.45 ± 26.51	1.37 ± 0.16	
MI/R +PAl (10)	58.60 ± 8.88	$189.63 \pm 33.87**$	$1.26 \pm 0.24*$	
MI/R +PAl (20)	$44.40 \pm 7.42*$	$142.12 \pm 18.57*$	$0.68 \pm 0.12*$	

Table 1. Effect of PAl on serum levels of TNF-α, IL-6, and ICAM-1

Values are expressed as the mean \pm SD (*n*=6)

*P<0.01, **P<0.05 vs. Model group; ***P<0.01 vs. Sham group.

Fig. 3. The results of MTT assay. a Viability of neonatal rat cardiomyocytes incubated for 24 h with PAl (0–3 mM) in normal conditions. b Protective effect of PAl (0.25, 0.5, and 1.0 mM) against SI/R-induced cell viability loss. Cells in the Control group (0 mM group or Con group) were considered 100 % viable. Data were presented as mean \pm SD (n=6). $\frac{p}{2}$ P < 0.01 vs. Control group, *P < 0.01 vs. SI/R group.

PAl Protected Cardiomyocytes Against Apoptosis Induced by SI/R

The anti-apoptotic effect of PAl was assessed by Hoechst 33258 staining and flow cytometry in the present study. Compared with the Con group, SI/R significantly increased the number of apoptotic cells with distinctive morphological changes including chromatin and/or cell nuclear fragmentation. However, the morphological changes were markedly attenuated by the pretreatment with different concentrations of PAl (Fig. [5\)](#page-6-0). A similar result was also observed in the result of a determination by flow cytometry. In the Con group, only a small number of cells were inviable. SI/R simulation, however, increased the percentage of apoptotic cells markedly $(P<0.01$, compared with the Con group) while pretreating the cardiomyocytes with PAl (0.25, 0.5, and 1.0 mM) reduced the apoptosis ratio significantly $(P<0.01$, compared with SI/R group) (Fig. [6\)](#page-6-0).

PAl Suppressed the Production of Inflammatory Mediators in the Culture Medium

As before, the levels of TNF- α and IL-6 in the culture medium were analyzed by ELISA. Compared with the Con group, SI/R resulted in notably increased levels of TNF- α and IL-6 in the supernatant $(P<0.01)$. However, the release of these two cytokines was greatly inhibited at the presence of PAl (0.25, 0.5, and 1.0 mM) compared with the SI/R group ($P < 0.05$, $P < 0.01$) (Fig. [7](#page-7-0)).

Likewise, as a crucial adhesion molecule involved in inflammatory cascades induced by I/R, the cell surface expression of ICAM-1 was also detected. The Western blot result showed that ICAM-1 expression was markedly upregulated in the SI/R group $(P<0.01$, compared with the Con group), but decreased significantly by the administration of PAI $(P<0.05, P<0.01,$ compared with SI/R group). As shown in Fig. [8](#page-7-0), PAl induced significant dose-dependent inhibition of ICAM-1expression.

Fig. 4. The effects of PAl on LDH and cTn-I activities in the culture medium of cardiomyocytes subjected to SI/R. a LDH activity; b cTn-I activity. The activities of LDH and cTn-I were determined by ELISA and expressed as percentage of control. Data are presented as mean \pm SD (n=6). $^{\#}P<0.01$ vs. Con group; ** P < 0.05, * P < 0.01 vs. SI/R group.

Fig. 5. The effect of PAl on nuclear morphology changes of cardiomyocytes subjected to SI/R. Apoptotic cells were confirmed by Hoechst 33258 staining (\times 400). a Con group; b SI/R group; c SI/R + PAl (0.25 mM) group; d SI/R + PAl (0.50 mM) group; e SI/R + PAl (1.0 mM) group.

Fig. 6. The effect of PAl on SI/R-induced cardiomyocytes apoptosis. Flow cytometric detection was performed to detect apoptotic ratio of neonatal rat cardiomyocytes in different groups. Data are presented as mean \pm SD of three independent experiments. \hbar = 0.01 vs. Con group, \hbar = 0.01 vs. SI/R group.

Fig. 7. The effects of PAl on TNF-α and IL-6 levels in the culture medium of cardiomyocytes subjected to SI/R. a TNF-α level; b IL-6 level. The levels of TNF- α and IL-6 were measured by ELISA and expressed as picograms per milliliter. Data were presented as mean \pm SD (n=6). $\frac{dp}{Q}$ = 6.01 vs. Con group; ** $P < 0.05$, * $P < 0.01$ vs. SI/R group.

PAl Modulated NF-κB Signaling Pathway Both In Vivo and In Vitro

The central role of NF-κB makes it an appealing focus for intervention by many drugs commonly used in cardiovascular disease. In the present study, the effect of PAl on the activation of NF-κB pathway was examined both in rats subjected to MI/R and in neonatal rat cardiomyocytes subjected to SI/R. In vitro, the changes in expression of NF-κB in cytosolic and nuclear extractions were first examined (Fig. [9a](#page-8-0)). In the SI/R

Fig. 8. The effect of PAl on ICAM-1 expression on neonatal rat cardiomyocytes subjected to SI/R. ICAM-1 expression was measured by Western blot analysis. ICAM-1 levels were corrected by β-actin and demonstrated as a fold of control. Data were presented as mean \pm SD of three independent experiments. $^{#}P<0.01$ vs. Con group, $^{*}P<0.01$ vs. SI/R group.

group, the cytosolic expression of NF-κB was significantly attenuated but enhanced notably in the nuclear fraction. However, this change was inhibited by pretreatment with PAl (1.0 mM). In addition, the phosphorylation of IκB- α was also examined. The data (Fig. [9b](#page-8-0)) showed that the phosphorylation of IκB-α increased significantly in the SI/R group compared with the Con group ($P < 0.01$), but was blocked to a large extent by the administration of PAI (1.0 mM) ($P < 0.01$, compared with the SI/R group). Interestingly, in vivo results (Fig. [10](#page-8-0)) showed an obvious similarity. MI/R not only increased the nuclear expression of NF-κB dramatically but also markedly degraded I κ B- α in cytoplasm (P<0.01, compared with the Sham group). However, different doses of PAI $(5, 10, \text{ and } 20 \text{ mg/kg})$ could inhibit the MI/Rinduced changes obviously $(P<0.05, P<0.01$, compared with the Model group).

DISCUSSION

Nowadays, studies of inflammatory lesions due to MI/R have been notably focused on endothelial cells and inflammatory cells [\[2](#page-9-0), [3](#page-10-0)], but little attention has been paid to myocardial cells which can be also induced to undergo inflammation in the MI/R process. In the current study, we combined in vivo experiments with rats and in vitro tests with cultured neonatal rat cardiomyocytes to explore the anti-inflammatory effect of PAl on myocardial injury induced by I/R. To the best of our knowledge, this is the first study to estimate the role of PAl against cellular injury induced by cardiomyocyte-mediated inflammation both in vivo and in vitro. The results showed that PAl could reduce MI/R

Fig. 9. The effect of PAl on the activation of NF-κB pathway in neonatal rat cardiomyocytes subjected to SI/R. a The effect of PAl on SI/R-induced nuclear translocation of NF-κB. The changes in expression of NF-κB in cytosolic and nuclear extractions were examined by Western blot analysis. b The effect of PAl on SI/R-induced IκB-α phosphorylation. Phospho-IκB-α levels were also measured by western blot analysis and corrected by βactin and demonstrated as a fold of control. Data are presented as mean \pm SD of three independent experiments. $\frac{H}{P}$ <0.01 vs. Con group, *P<0.01 vs. SI/R group.

injury in rat and SI/R injury in cultured cardiomyocytes on one hand and decrease the levels of inflammatory mediators in serum and culture medium on the other hand. In addition, the transcription factor NF-κB was closely involved in these therapeutic effects. This was manifested by increased NF-κB nuclear translocation and promoted phosphorylation or degradation of IκB-α.

As mentioned before, many inflammatory mediators are involved in myocardial damage due to MI/R. TNF- α , IL-6, and ICAM-1 are three essential ones, which have tight interactions with each other. The synthesis and release of TNF- α is the initial event of inflammatory responses induced by I/R [\[4](#page-10-0)]. It is capable of inducing different kinds of proinflammatory mediators, such as IL-6 [\[24\]](#page-10-0) and ICAM-1 [\[25](#page-10-0)] to express in/on cardiac myocytes exposed to I/R. Also, IL-6 synthesis is an integral part of the response to injury resulting from I/R and relates to the induction of ICAM-1 on cardiac myocytes. Studies demonstrated that the expression of ICAM-1 on cardiac myocytes was upregulated by IL-6 [\[24,](#page-10-0) [26](#page-10-0)]. The formation of mass ICAM-1 conduced to enhanced neutrophil adhesion and leukocyte infiltration to myocardium subjected to I/R [\[27](#page-10-0)]. Then the activated neutrophils release large amounts of oxygen radicals, reactive oxygen species, and cytotoxic molecules, resulting in cardiac dysfunction and myocardial cell death [[28\]](#page-10-0).

Obviously, inflammatory cascades mediated by cytokines and adhesion molecules including TNF- α ,

Fig. 10. The effect of PAl on the activation of NF-κB pathway in rats subjected to MI/R. a The effect of PAl on nuclear expression of NF-κB in myocardial tissue from rats subjected to MI/R. b The effect of PAl on the degradation of IκB-α in cytosolic fractions from rats subjected to MI/R. The levels of NF-κB in nuclear fractions and IκB-α in cytosolic fractions were examined by Western blot analysis and corrected by PCNA and β-actin respectively. Data are presented as mean \pm SD of three independent experiments. $^{#}P<0.01$ vs. Sham group; **P<0.05, *P<0.01 vs. Model group.

IL-6, and ICAM-1 are closely related to MI/R injury. Thus, inhibiting this process will contribute to cardioprotection. In our study, PAl significantly decreased the levels of TNF- α , IL-6, and ICAM-1 both *in vivo* and *in* vitro. This fact indicated that PAl may have a pivotal role in alleviating the acute inflammatory injury caused by I/R. Interestingly, our research confirmed that PAl preserved cardiomyocytes against the injury induced by MI/R in vivo and SI/R in vitro. In the study, PAl pretreatment significantly reduced myocardial infarct size and serum levels of CK-MB and cTn-I after I/R injury. Not only that, the elevated LDH and cTn-I activities in the culture medium and increased percentage of apoptotic cells induced by SI/R were also markedly decreased by PAl administration. Based on all of the observations mentioned above, we can conclude that PAl can exert a strong anti-inflammatory effect both in rats subjected to MI/R and cultured neonatal rat cardiomyocytes suffering SI/R, and suppression of the inflammatory response afforded by PAl may be responsible for its beneficial effect on myocardial injury.

Since the anti-inflammatory effect and the protection on cardiomyocyte of PAl were defined, further study was performed to investigate the possible mechanisms. Given the fact that NF-κB is a ubiquitously expressed transcription factor [[29\]](#page-10-0) and has a significant position both in inflammatory response and cell survival in the MI/R process [\[15](#page-10-0), [30\]](#page-10-0), our study was centered on NFκB signaling pathway. In fact, NF-κB has been the focus of intense investigation for nearly two decades. Considerable progress has been made in determining the regulation of NF-κB. As we know, in its inhibited form, NF-κB dimer is segregated in the cytoplasm bound to an inhibitory protein known as IκB. Inhibition is relieved by various stimuli including I/R, which firstly results in the phosphorylation of IκB and its subsequent degradation via the proteosomes. After that, the released NF-κB is translocated to the nucleus and binds to the promoter or enhancer of specific genes, leading to the activation of those encoding cytokines, and intercellular adhesion molecules [\[8](#page-10-0), [31](#page-10-0), [32](#page-10-0)]. Thus, it can be perceived that a curb on the NF-κB signaling pathway is bound to be implicated in the regulation of I/R-induced inflammatory reactions. In the present study, both MI/R in vivo and SI/R in vitro promoted the nuclear translocation of NF-κB as well as phosphorylation or degradation of IκB-α markedly; however, PAl administration greatly inhibited these changes. The results indicated that the anti-inflammatory effect and myocardial protection of PAl relied heavily on the inhibition of NF-κB signaling pathway.

It is sure that our research may have some limitations. First, although PAl clearly reduced the inflammatory markers, as well as alleviated myocardial injury significantly, it could not directly prove that PAl exerted its myocardial protection solely through antiinflammatory effect; more compelling evidence should be provided to support the hypothesis. Second, we have not proved in which way PAl may regulate the NF-κB signaling pathway; further studies are needed to clarify its effect on upstream regulation of NF-κB activation.

In summary, the present study has demonstrated that PAl could provide cardioprotection against MI/R injury in rat and SI/R injury in myocardial cells. The results indicated that PAl reduced myocardial infarct size, the releases of CK-MB, cTn-I in serum, and the activities of LDH, cTn-I in the culture medium, as well as decreased the ratio of cell apoptosis. These protective effects of PAl were associated with decreased levels of TNF-α, IL-6, ICAM-1, phosphorylated IκB-α, and activated NF-κB proteins. These observations suggested that the protective effects of PAl could be due, in large part, to the suppression of the inflammatory response via inhibition of NF-κB activation. These findings pointed to the therapeutic potential of PAl as a useful anti-inflammatory lead compound in MI/R injury.

ACKNOWLEDGMENTS

This study was supported by the National Natural Science Foundation of China (ADW, no. 81173514), National Natural Science Foundation of China (MMX, no. 81001673), the "13115" Technology Innovation Project of Shaanxi Province (MMX, no. 2010ZDKG-62), Natural Science Foundation of Shaanxi Province (MMX, no. 2010JQ4018), Xijing Research Boosting Program (MMX, no. XJZT10D02), and Excellent Civil Service Training Fund of Forth Military Medical University (YG, no. 4138C4IDK6).

Conflicts of Interest. The authors have no conflicting financial interests.

REFERENCES

- 1. Yellon, D.M., and D.J. Hausenloy. 2007. Myocardial reperfusion injury. The New England Journal o f Medicine 357: 1121–1135.
- 2. Frangogiannis, N.G., C.W. Smith, and M.L. Entman. 2002. The inflammatory response in myocardial infarction. Cardiovascular Research 53: 31–47.
- 3. Nah, D.Y., and M.Y. Rhee. 2009. The inflammatory response and cardiac repair after myocardial infarction. Korean Circulation Journal 39: 393–398.
- 4. Frangogiannis, N.G., M.L. Lindsey, L.H. Michael, K.A. Youker, R.B. Bressler, L.H. Mendoza, R.N. Spengler, C.W. Smith, and M.L. Entman. 1998. Resident cardiac mast cells degranulate and release preformed TNF-a, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 98: 699–710.
- 5. Ke, J.J., F.X. Yu, Y. Rao, and Y.L. Wang. 2011. Adenosine postconditioning protects against myocardial ischemia–reperfusion injury though modulate production of TNF-a and prevents activation of transcription factor NF-kappaB. Molecular Biology Reports 38: 531-538.
- 6. Kukielka, G.L., H.K. Hawkins, L. Michael, A.M. Manninget, K. Youker, C. Lane, M.L. Entman, C.W. Smith, and D.C. Anderson. 1993. Regulation of intercellular adhesion molecule-1 (ICAM-1) in ischemic and reperfused canine myocardium. The Journal of Clinical Investigation 92: 1504–1516.
- 7. Gurevitch, J., I. Frolkis, Y. Yuhas, B. Lifschitz-Mercer, E. Berger, Y. Paz, M. Masta, A. Kramer, and P. Mohr. 1997. Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. Journal of the American College of Cardiology 30: 1554–1561.
- 8. Onai, Y., J.I. Suzuki, T. Kakuta, Y. Maejima, G. Haraguchi, H. Fukasawa, S. Muto, A. Itai, and M. Isobe. 2004. Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovascular Research 63: 51–59.
- 9. Braunersreuthera, V., C. Pellieuxa, G. Pellia, F. Burger, S. Steffens, C. Montessuit, C. Weber, A. Proudfoot, F. Mach, and C. Arnaud. 2010. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. Journal of Molecular and Cellular Cardiology 48: 789–798.
- 10. Yuan, Z.F., G.X. Fan, B.B. Wang, Z.Y. He, and P.Q. Shu. 2008. Myocardial protective effect of Danshen injection in patients undergoing open heart surgery. Journal of Clinical Medicine in Practice 12: 12–14.
- 11. Zhou, R., L.F. He, Y.J. Li, Y. Shen, R.B. Chao, and J.R. Du. 2012. Cardioprotective effect of water and ethanol extract of Salvia miltiorrhiza in an experimental model of myocardial infarction. Journal of Ethnopharmacology 139: 440–446.
- 12. Qiao, Z.Y., J.W. Ma, and H.J. Liu. 2011. Evaluation of the antioxidant potential of Salvia miltiorrhiza ethanol extract in a rat model of ischemia–reperfusion injury. Molecules 16: 10002–10012.
- 13. Zhou, Z., Y. Liu, A.D. Miao, and S.Q. Wang. 2005. Protocatechuic aldehyde suppresses TNF-a-induced ICAM-1 and VCAM-1 expression in human umbilical vein endothelial cells. European Journal of Pharmacology 513: 1–8.
- 14. Han, C.J., R. Lin, J.T. Liu, Y. Liu, and H. Zhang. 2007. Protection of vascular endothelial cells from ox-LDL induced injury by protocatechualdehyde. Journal of Chinese Medicinal Materials 30: 1541–1544.
- 15. Frantz, S., J. Tillmanns, P.J. Kuhlencordt, I. Schmidt, A. Adamek, C. Dienesch, T. Thum, S. Gerondakis, G. Ertl, and J. Bauersachs. 2007. Tissue-specific effects of the nuclear factor κB subunit p50 on myocardial ischemia–reperfusion injury. The American Journal of Pathology 171: 507–512.
- 16. Zhu, J., Y. Qiu, Q. Wang, Y. Zhu, S. Hu, L. Zheng, L. Wang, and Y. Zhang. 2008. Low dose cyclophosphamide rescues myocardial function from ischemia–reperfusion in rats. European Journal of Cardio-Thoracic Surgery 34: 661–666.
- 17. Zhang, J.Y., Z.W. Chen, and H. Yao. 2012. Protective effect of urantide against ischemia–reperfusion injury via protein kinase C

and phosphtidylinositol 3′-kinase–Akt pathway. Canadian Journal of Physiology and Pharmacology 90: 637–645.

- 18. Ren, Z.H., Y.H. Tong, W. Xu, J. Ma, and Y. Chen. 2010. Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine 17: 212–218.
- 19. Li, J., H.F. Zhang, F. Wu, Y. Nan, H. Ma, W.Y. Guo, H.C. Wang, J. Ren, U.N. Das, and F. Gao. 2008. Insulin inhibits tumor necrosis factor-α induction in myocardial ischemia/reperfusion: role of Akt and endothelial nitric oxide synthase phosphorylation. Critical Care Medicine 36: 1551–1558.
- 20. Cao, C.M., Y. Zhang, N. Weisleder, C. Ferrante, X.H. Wang, J.J. Ma, and R.P. Xiao. 2010. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121: 2565–2574.
- 21. Etievent, J.P., S. Chocron, G. Toubin, C. Taberlet, K. Alwan, F. Clement, A. Cordier, N. Schipman, and J.P. Kantelip. 1995. Use of cardiac troponin I as a marker of perioperative myocardial ischemia. The Annals of Thoracic Surgery 59: 1192–1194.
- 22. Lin, L., X.D. Wu, A.K. Davey, and J.P. Wang. 2010. The antiinflammatory effect of Baicalin on hypoxia/reoxygenation and TNF-α induced injury in cultural rat cardiomyocytes. Phytotherapy Research 24: 429–437.
- 23. Freude, B., T.N. Masters, F. Robicsek, A. Fokin, S. Kostin, R. Zimmermann, C. Ullmann, S. Lorenz-Meyer, and J. Schaper. 2000. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. Journal of Molecular and Cellular Cardiology 32: 197–208.
- 24. Gwechenberger, M., L.H. Mendoza, K.A. Youker, N.G. Frangogiannis, C.W. Smith, L.H. Michaelet, and M.L. Entman. 1999. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99: 546–551.
- 25. Kacimi, R., J.S. Karliner, F. Koudssi, and C.S. Long. 1998. Expression and regulation of adhesion molecules in cardiac cells by cytokines: response to acute hypoxia. Circulation Research 82: 576–586.
- 26. Kukielka, G.L., C.W. Smith, A.M. Manning, K.A. Youkeret, L.H. Michael, and M.L. Entman. 1995. Induction of interleukin-6 synthesis in the myocardium potential role in postreperfusion inflammatory injury. Circulation 92: 1866–1875.
- 27. Smith, C.W., M.L. Entman, C.L. Lane, A.L. Beaudet, T.L. Ty, K. Youker, H.K. Hawkins, and D.C. Anderson. 1991. Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intercellular adhesion molecule-1. The Journal of Clinical Investigation 88: 1216–1223.
- 28. Vinten-Johansen, J. 2004. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovascular Research 61: 481–497.
- 29. Jones, W.K., M. Brown, M. Wilhide, S.W. He, and X.P. Ren. 2005. NFκB in cardiovascular disease: diverse and specific effects of a "general" transcription factor? Cardiovascular Toxicology 05: 183–201.
- 30. Kim, J.W., Y.C. Jin, Y.M. Kim, S. Rhie, H.J. Kim, H.G. Seo, J.H. Lee, Y.L. Ha, and K.C. Chang. 2009. Daidzein administration in vivo reduces myocardial injury in a rat ischemia/reperfusion model by inhibiting NF-κB activation. Life Sciences 84: 227–234.
- 31. Yeh, C.H., T.P. Chen, Y.C. Wu, and Y.M. Lin. 2005. Inhibition of NFκB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/ reperfusion. The Journal of Surgical Research 125: 109–116.
- 32. Nichols, T.C. 2004. NF-κB and reperfusion injury. Drug News & Perspectives 17: 99.